Vistagen Therapeutics (VTGN) News Today → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free VTGN Stock Alerts $4.46 +0.02 (+0.45%) (As of 02:27 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16, 2024 | americanbankingnews.comVistagen Therapeutics (NASDAQ:VTGN) Stock Passes Above 50-Day Moving Average of $4.65May 14, 2024 | investorplace.com3 Must-Have Penny Stocks to Boost Your 2024 PortfolioMay 13, 2024 | investorplace.comMeme Stock Rebound: 3 Reddit Favorites Primed for a ResurgenceMay 8, 2024 | marketbeat.comVistagen Therapeutics (NASDAQ:VTGN) Share Price Crosses Below 50-Day Moving Average of $4.69Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Below 50 Day Moving Average of $4.69May 7, 2024 | businesswire.comVistagen to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceApril 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Acrivon Therapeutics, Inc. (ACRV)April 26, 2024 | msn.comVistagen reports positive results for mental fatigue treatmentApril 25, 2024 | businesswire.comVistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental FatigueApril 24, 2024 | seekingalpha.comVistagen Therapeutics: A Pipeline With Potential In Anxiety And DepressionApril 19, 2024 | investorplace.com7 Stocks Under $15 Predicted to Boom in the Next 2 YearsApril 9, 2024 | investorplace.comMillionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027April 9, 2024 | businesswire.comVistagen to Present at the 2024 Anxiety and Depression Association (ADAA) ConferenceApril 1, 2024 | finance.yahoo.comVistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2March 31, 2024 | investorplace.comSecret Superstars: 3 Unknown Stocks to Turn $5K into $100K by 2027March 28, 2024 | msn.comPDS Biotechnology GAAP EPS of -$1.39 beats by $0.06March 26, 2024 | finance.yahoo.com30 Countries with the Lowest Depression RatesMarch 20, 2024 | marketbeat.comVistagen Therapeutics (NASDAQ:VTGN) Share Price Crosses Below 50-Day Moving Average of $4.83Vistagen Therapeutics (NASDAQ:VTGN) Stock Passes Below Fifty Day Moving Average of $4.83March 17, 2024 | seekingalpha.comWhy VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety TreatmentsMarch 16, 2024 | finance.yahoo.comVTGN Apr 2024 10.000 callMarch 15, 2024 | cnbc.comThis overlooked corner of women's health could be a $350 billion market opportunityMarch 11, 2024 | businesswire.comVistagen to Present at Stifel 2024 Virtual CNS DaysFebruary 28, 2024 | finance.yahoo.comVistagen to Present at TD Cowen 44th Annual Health Care ConferenceFebruary 28, 2024 | businesswire.comVistagen to Present at TD Cowen 44th Annual Health Care ConferenceFebruary 22, 2024 | benzinga.comVistagen Therapeutics Stock (NASDAQ:VTGN), Short Interest ReportFebruary 21, 2024 | finance.yahoo.comDoes VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect?February 19, 2024 | investorplace.com3 Revolutionary Biotech Stocks Poised for 10X SurgeFebruary 16, 2024 | marketbeat.comFY2024 EPS Estimates for Vistagen Therapeutics, Inc. Boosted by Analyst (NASDAQ:VTGN)Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) - Stock analysts at William Blair lifted their FY2024 earnings per share estimates for shares of Vistagen Therapeutics in a research report issued to clients and investors on Tuesday, February 13th. William Blair analyst T. Lugo now expectsFebruary 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for VistaGen: Promising Clinical Results and Strong Financial OutlookFebruary 15, 2024 | finance.yahoo.comVistagen Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagFebruary 15, 2024 | finance.yahoo.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2024 Earnings Call TranscriptFebruary 14, 2024 | investorplace.com3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market WaveFebruary 13, 2024 | morningstar.comVistagen Therapeutics Inc VTGNFebruary 13, 2024 | benzinga.comRecap: Vistagen Therapeutics Q3 EarningsFebruary 13, 2024 | msn.comVistagen Therapeutics files for $350M mixed shelfFebruary 13, 2024 | finance.yahoo.comVistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate UpdateFebruary 13, 2024 | finance.yahoo.comVistagen Therapeutics Inc (VTGN) Reports Fiscal 2024 Q3 Results: A Closer Look at Financials ...February 13, 2024 | businesswire.comVistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate UpdateFebruary 12, 2024 | msn.comVistaGen Therapeutics Q3 2024 Earnings PreviewFebruary 12, 2024 | benzinga.comVistaGen Therapeutics's Earnings: A PreviewFebruary 7, 2024 | finance.yahoo.comVistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024February 7, 2024 | marketbeat.comVistagen Therapeutics (VTGN) Set to Announce Quarterly Earnings on TuesdayVistagen Therapeutics (NASDAQ:VTGN) will be releasing earnings after the market closes on Tuesday, February 13, Zacks reports.February 3, 2024 | marketbeat.comVistagen Therapeutics (NASDAQ:VTGN) Share Price Crosses Above Fifty Day Moving Average of $4.86Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above Fifty Day Moving Average of $4.86January 30, 2024 | investing.comVistaGen Therapeutics Inc (VTGN)January 26, 2024 | marketbeat.comVistagen Therapeutics, Inc. (NASDAQ:VTGN) Sees Large Drop in Short InterestVistagen Therapeutics, Inc. (NASDAQ:VTGN - Get Free Report) was the recipient of a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 1,160,000 shares, a decrease of 28.8% from the December 31st total of 1,630,000 shares. Based on an average trading volume of 544,700 shares, the days-to-cover ratio is presently 2.1 days. Approximately 4.8% of the shares of the stock are sold short.January 23, 2024 | thestreet.comVistagen Therapeutics Inc.December 29, 2023 | finance.yahoo.comHow Vistagen (VTGN) Stock Stands Out in a Strong IndustryDecember 27, 2023 | finance.yahoo.comVistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic PainDecember 16, 2023 | msn.comVistaGen Therapeutics (VTGN) Price Target Increased by 8.33% to 13.26December 15, 2023 | marketbeat.comVistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Down 21.4% in NovemberVistagen Therapeutics, Inc. (NASDAQ:VTGN - Get Free Report) was the target of a large decrease in short interest in November. As of November 30th, there was short interest totalling 1,250,000 shares, a decrease of 21.4% from the November 15th total of 1,590,000 shares. Based on an average trading volume of 583,000 shares, the short-interest ratio is presently 2.1 days. Approximately 5.1% of the company's shares are short sold.December 8, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Bioventus (BVS), Cerevel Therapeutics Holdings (CERE) and VistaGen Therapeutics (VTGN) Get Vistagen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Email Address This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world. Click here to learn more about the booming eHealth industry VTGN Media Mentions By Week VTGN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VTGN News Sentiment▼0.000.42▲Average Medical News Sentiment VTGN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VTGN Articles This Week▼22▲VTGN Articles Average Week Get Vistagen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ABEO News IMUX News RNAC News KPTI News COYA News NVCT News CLRB News AMLX News OPTN News SCTL News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VTGN) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldProtect Your Bank Account Before It’s Too LateWeiss RatingsThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsThis Could be Your “Big Money” AI MomentInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vistagen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
